Tokyo, Japan

Masayoshi Jin

This inventor holds 4 USPTO granted patents and 2 EPO patents. Top assignees: Daiichi Sankyo Company, Limited, Plexxikon Inc.. Active years: 2017-2020.


% Patents Active = 100.0

 

Average Co-Inventor Count = 3.0

ph-index = 4

Forward Citations = 45(Granted Patents)


Company Filing History:


Years Active: 2017-2020

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Masayoshi Jin: Innovator in Kinase Modulation

Introduction

Masayoshi Jin is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of biochemistry, particularly in the synthesis of compounds that modulate kinases. With a total of 4 patents to his name, Jin's work has implications for various therapeutic applications.

Latest Patents

One of Jin's latest patents involves the synthesis of a compound that modulates kinases. The present disclosure provides processes for the preparation of a compound of formula I, or a salt thereof, that is active on the receptor protein kinases c-Kit, c-Fms, and Flt3. This patent also includes compounds and processes for the preparation of synthetic intermediates to the compound of formula I.

Career Highlights

Throughout his career, Masayoshi Jin has worked with notable companies in the pharmaceutical industry. He has been associated with Daiichi Sankyo Company, Limited and Plexxikon Inc., where he has contributed to innovative research and development projects.

Collaborations

Some of his notable coworkers include Prabha N Ibrahim and Shinji Matsuura. Their collaborative efforts have further advanced the research in kinase modulation.

Conclusion

Masayoshi Jin's contributions to the field of biochemistry through his innovative patents and collaborations highlight his role as a key inventor in the synthesis of kinase-modulating compounds. His work continues to influence therapeutic advancements in medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…